| Document |
Document Title |
|
WO/2013/037960A1 |
The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for ...
|
|
WO/2013/033955A1 |
Provided are a benzoxazine monomer comprising benzocyclobutenyl functional group, synthetic method therefor and use thereof. The benzoxazine monomer comprising benzocyclobutene monomer may be synthesized via two routes: 1. subjecting ami...
|
|
WO/2013/033245A1 |
The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds...
|
|
WO/2013/022595A1 |
The present disclosure provides a method for producing a benzoxazine compound by reacting a phenolic compound with an aldehyde compound and an amine compound in the presence of a solvent system containing a apolar solvent and a polar apr...
|
|
WO/2013/007371A2 |
The present invention refers to a method for the kinetic resolution of a chiral primary or secondary amine by treating the amine with a chiral, hydroxamic acid derived reagent of the formula (I). These chiral reagents are particularly us...
|
|
WO/2013/000651A1 |
Fluorinated arylalkylaminocarboxamide derivatives of formula (I) are described wherein W, J, n, R1, R2, R2', R3, R4, R5 and R6 have the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositi...
|
|
WO/2012/168265A1 |
The present invention relates to compounds of formula (I) wherein R1 is hydrogen, halogen, cyano, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen or C(O)NH2, or is phenyl optionally subs...
|
|
WO/2012/160392A1 |
The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, m and n are as defined in the specification. T...
|
|
WO/2012/156284A1 |
The present invention provides compounds of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds ...
|
|
WO/2012/154204A1 |
Antibacterial compounds of Formula I are provided: as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administrat...
|
|
WO/2012/154760A1 |
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...
|
|
WO/2012/146692A1 |
The invention provides a salt, preferably in crystalline form, of (2R,3S)-2-[(R)-1-(3,5-Bis- trifluoromethylphenyl)ethoxy]-3-(4-fluorophenyl)morpholine (BFM2) with a Ο,Ο'-substituted tartaric acid derivative. Furthermore, a composition...
|
|
WO/2012/139993A1 |
The present invention provides 4-(3-Amino-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-ylamines of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therape...
|
|
WO/2012/140061A1 |
The present invention relates to methods for the preparation of a compound having the formula (X). Individual reaction steps as welt as intermediates are additionally claimed.
|
|
WO/2012/136655A1 |
The present invention relates to compounds useful in the treatment of amyloid diseases, such as Alzheimer's disease. Further, the compounds are useful for imaging amyloid deposits.
|
|
WO/2012/126922A1 |
The present invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, nitro, C3-6-cycloalkyl, -CH2-C3-6-cyclo...
|
|
WO/2012/127385A1 |
Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (Ca SR) recept...
|
|
WO/2012/128582A2 |
The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. ...
|
|
WO/2012/127388A1 |
Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) recepto...
|
|
WO/2012/124719A1 |
A compound having a benzoxazinone ring and an aromatic ring that is bound directly to the benzoxazinone ring and also having a mesogenic core substituted by a substituent having a polymerizable functional group. The compound has excellen...
|
|
WO/2012/124775A1 |
The present invention provides a nitrogen-containing saturated heterocyclic compound that is useful as a renin inhibitor/antagonist. A compound represented by formula [I] or a pharmaceutically acceptable salt thereof. (In the formula, R1...
|
|
WO/2012/120476A1 |
Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (Ca SR) recept...
|
|
WO/2012/120423A1 |
The present invention relates to a compound of formula (I) below: or a pharmaceutically acceptable salt thereof, for the use thereof in the prevention or treatment of cancers.
|
|
WO/2012/119927A1 |
The invention relates to a method for producing primary amines comprising at least one functional group of formula (-CH2-NH2), by alcohol amination of educts which comprise at least one functional group of formula (–CH2-OH), using ammo...
|
|
WO/2012/110833A2 |
The present invention relates to fluorescence lifetime modulators, conjugates comprising fluorescence lifetime modulators moieties and methods of making them. The present invention further relates to the use of the fluorescence lifetime ...
|
|
WO/2012/104865A1 |
"An insect repelling compound and a process for preparation thereof. The present invention discloses a compound of formula I and a process for preparation thereof. The compound exhibits insect repellent properties. The invention also dis...
|
|
WO/2012/101245A1 |
The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula (I) QAaBbCc where a is 0, 1, 2, 3, 4 or 6, b ...
|
|
WO/2012/098064A1 |
The present invention relates to 1,4 Oxazines of formula (I): having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active co...
|
|
WO/2012/097510A1 |
The invention disclosed a process for the preparation of the HIV drug Efavirenz, also known as DMP-266, starting from 1,4-dichlorobenzene, and its intermediates.
|
|
WO/2012/097511A1 |
Disclosed is a method for the preparation of the HIV drug Efavirenz, also known as DMP-266, starting from 1,4-dichlorobenzene, and its intermediates.
|
|
WO/2012/095803A1 |
Disclosed are fluorescent compounds with large Stokes-shift and a process for their preparation. More particularly, disclosed are fluorescent compounds that are colourless. The compounds can be used in compositions for inks, paints and p...
|
|
WO/2012/092873A1 |
Disclosed in the present invention are a synthetic Rivaroxaban intermediate and a preparation method thereof. The method comprises: morpholine-3-one and 4-fluoro nitrobenzene are used as the raw materials to obtain a compound of formula ...
|
|
WO/2012/094622A2 |
Embodiments of the invention provide methods and materials for chemical cross-coupling reactions that utilize aryl alcohol derivatives as cross-coupling partners. Embodiments of the invention include methods for the amination of aryl sul...
|
|
WO/2012/090177A2 |
Compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. M...
|
|
WO/2012/088314A1 |
Compounds and compositions comprising compounds including formula (I) that activate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that activate PKM2 in the treatment of cancer.
|
|
WO/2012/087720A1 |
Disclosed is a process for making diastereomeric compound of the formula (I): wherein m, n and R1 to R4 are as defined herein. The process of the invention provides the compound of formula (I) in high yield and substantially free of the ...
|
|
WO/2012/079235A1 |
The invention disclosed a 4 step process for the preparation of Efavirenz, starting from 1,4-dichlorobenzene, and its intermediates.
|
|
WO/2012/081585A1 |
The present invention provides a method for diastereo-selectively and enantioselectively producing an optically active alcohol compound indicated in formula (IIIa), etc., that includes hydrogenation of a carbonyl compound indicated in fo...
|
|
WO/2012/081582A1 |
The present invention provides a method for diastereo-selectively synthesizing an alcohol compound, that includes hydrogenation of a carbonyl compound indicated in formula (I) in the presence of a ruthenium compound indicated in formula ...
|
|
WO/2012/076794A1 |
The present invention relates to a process for functionalizing at least one ribonucleic acid (RNA) molecule, which comprises the following steps: a) providing at least: one linker molecule consisting of an isatoic anhydride or a derivati...
|
|
WO/2012/076428A1 |
Polytetrahydrobenzoxazines and bistetrahydrobenzoxazines obtainable by (A) reaction of at least one diamine of formula H2N-A-NH2 with a C1 to C12 aldehyde and a C1 to C8 alkanol at 20 to 80°C with elimination and removal of water, (B) r...
|
|
WO/2012/067139A1 |
Provided is a compound represented by general formula (1). (In the formula, R1 represents a C1-20 aliphatic hydrocarbon group which may have a substituent; and R2-R13 independently represent a hydrogen atom, a halogen atom, or an aromati...
|
|
WO/2012/051692A1 |
Provided are process for the preparation of (R)- and/or (S)- Rivaroxaban, and compounds which are intermediate compounds used in the processes for the preparation of (R)- and/or (S)-Rivaroxaban.
|
|
WO/2012/048884A1 |
The invention is directed to a process for the preparation of a cyclic carbamate starting with a chiral propargylic alcohol and/or a suitable salt thereof, which is reacted with a cyclisation agent selected from phosgene, diphosgene, tri...
|
|
WO/2012/048886A1 |
The invention is directed to a process for the preparation of a cyclic carbamate starting with o-aminobenzyl alcohol and/or a suitable salt thereof, which is reacted with a cyclisation agent selected from phosgene, diphosgene, triphosgen...
|
|
WO/2012/038942A1 |
This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonar...
|
|
WO/2012/036233A1 |
Provided is a novel compound which has MCH R1 receptor antagonistic activity and is represented by formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the same. (In the formula, the portion AA represented by formula ...
|
|
WO/2012/031298A2 |
Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-ne...
|
|
WO/2012/025935A2 |
The invention provides a novel process for the synthesis of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one, the process comprising of reacting the salicylic acid with salicylamide in the presence of p-toluenesulfonyl chloride, base and solven...
|
|
WO/2012/020742A1 |
Disclosed is a novel compound that acts as an antagonist for P2X3 and/or P2X2/3 receptors. Also disclosed is a pharmaceutical composition that acts as an antagonist for P2X3 and/or P2X2/3 receptors, said composition containing: a compoun...
|
